Raleigh Capital Management Inc. Sells 558 Shares of Sanofi (NASDAQ:SNY)

Raleigh Capital Management Inc. decreased its stake in shares of Sanofi (NASDAQ:SNY) by 1.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,841 shares of the company’s stock after selling 558 shares during the quarter. Raleigh Capital Management Inc.’s holdings in Sanofi were worth $1,893,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Stablepoint Partners LLC raised its stake in shares of Sanofi by 0.8% in the third quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock worth $1,377,000 after buying an additional 189 shares during the period. TCTC Holdings LLC lifted its stake in shares of Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock valued at $47,000 after buying an additional 210 shares in the last quarter. HB Wealth Management LLC raised its holdings in Sanofi by 3.7% during the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after acquiring an additional 221 shares during the period. Insigneo Advisory Services LLC boosted its stake in shares of Sanofi by 3.3% in the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after acquiring an additional 228 shares during the period. Finally, Pinnacle Bancorp Inc. raised its stake in Sanofi by 24.6% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 1,227 shares of the company’s stock valued at $71,000 after purchasing an additional 242 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

SNY stock opened at $53.66 on Tuesday. Sanofi has a 52 week low of $42.63 and a 52 week high of $58.97. The firm has a market capitalization of $136.16 billion, a P/E ratio of 29.16, a price-to-earnings-growth ratio of 1.57 and a beta of 0.60. The company has a fifty day simple moving average of $56.13 and a two-hundred day simple moving average of $51.62. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to the consensus estimate of $16.86 billion. During the same quarter last year, the firm earned $0.95 EPS. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. Analysts anticipate that Sanofi will post 4.25 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently commented on SNY shares. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.